StephanieJ.(Nahas)Nahas-GeigerMD

Neurology • Philadelphia, PA

Headache

Associate Professor, Neurology, Thomas Jefferson University

Join to view full profile

Dr. Nahas-Geiger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nahas-Geiger's full profile

Already have an account?

Office
900 Walnut St
Ste 200
Philadelphia, PA 19107
Phone+1 215-955-2243

Fax+1 215-955-2060

Summary

Dr. Stephanie Nahas is a neurologist with subspecialty certification in headache medicine practicing in Philadelphia, PA. She is affiliated with Thomas Jefferson University Hospitals. She received her medical degree from Rush Medical College in 2001, completed neurology residency in 2005, followed by fellowship in headache medicine, and has been on faculty at Jefferson since January 2017.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Headache Medicine, 2005 - 2007
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 2002 - 2005
Rush University Medical CenterInternship, Internal Medicine, 2001 - 2002
Rush Medical College of Rush University Medical CenterClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
PA State Medical License 2002 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Fellow American Headache Society
Fellow American Academy of Neurology

Publications & Presentations

PubMed

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine.
Jessica Ailani, Pranav Gandhi, Anjana Lalla, Rashmi Halker Singh, Peter McAllister
Headache. 2024-09-09
2 citations
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
Richard B Lipton, Stephanie J Nahas, Patricia Pozo-Rosich, Tanya Bilchik, Peter McAllister
The Journal of Headache and Pain. 2024-05-21
2 citations
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
Paul Rizzoli, Michael J Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco
The Journal of Headache and Pain. 2024-03-11

Lectures

A Practical Approach to Migraine Management

Press Mentions

Migraine Nasal Spray with Novel Delivery System Gains FDA ApprovalSeptember 20th, 2021
Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD TechnoloSeptember 4th, 2021
FDA Approves DHE-Based Migraine Treatment TrudhesaSeptember 3rd, 2021
Join now to see all